Last edition
News about Global Pharma
Foresee Pharmaceuticals has received US FDA approval for CAMCEVI ETM (21 mg) as a treatment for advanced prostate cancer.
Global Pharma | 30/08/2025 | By Mrinmoy Dey | 447
US FDA Clears Sanofi's Wayrilz, First BTK Inhibitor for ITP
The US FDA approval was based on the pivotal LUNA 3 phase-III study, in which Sanofi’s Wayrilz met the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other ITP symptoms.
Global Pharma | 30/08/2025 | By Dineshwori | 281
Teva Pharmaceuticals Launches First Generic Version of Saxenda in US
The first generic version of Saxenda, Liraglutide injection, is approved for adults with obesity or overweight who have weight-related medical conditions, as well as for paediatric patients aged 12 to 17 years weighing more than 60 kg with obesity.
Global Pharma | 30/08/2025 | By Dineshwori | 793
OPTEL Acquires Vanguard Robotics to Accelerate Innovation in Pharma Automation
OPTEL Group has acquired Vanguard Robotics to strengthen its pharmaceutical automation portfolio with advanced end-of-line cobot solutions.
Global Pharma | 29/08/2025 | By Mrinmoy Dey | 287
Celaid Therapeutics and AGC Ink Research Pact on iPSC-HSPC Expansion and Evaluation
Celaid Therapeutics has partnered with AGC Inc. to advance scalable expansion of iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs) by combining their respective stem cell technologies.
Global Pharma | 29/08/2025 | By Mrinmoy Dey | 107
Pacific Software Acquires 107 Canada from PurMinds
Pacific Software Inc. has acquired 10763942 Canada Inc. (107 Canada) and its PurMinds asset portfolio, strengthening its position in clinical-stage neuromedicine with a pipeline targeting neurological and psychiatric disorders.
Global Pharma | 27/08/2025 | By Mrinmoy Dey | 143
Clyra Medical Technologies Appoints David Zansitis as Vice President of Clinical Affairs
In this new role, David Zansitis will provide strategic clinical leadership, partnering with Clyra’s Chief Medical Officer to expand the company’s clinical roadmap.
Global Pharma | 27/08/2025 | By Dineshwori | 162
AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal
AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.
Global Pharma | 26/08/2025 | By Mrinmoy Dey | 200
Scenic Biotech Partners with Alnylam to Advance RNAi Therapeutics Using Cell-Seq Platform
This collaboration represents Scenic Biotech’s third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. <br />
Global Pharma | 26/08/2025 | By Dineshwori | 285
Er-Kim Partners with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey
Istanbul-based Er-Kim, an international pharmaceutical company specialising in the commercialisation of novel therapies, has entered into a distribution agreement with UK-based CNX Therapeutics to supply selected oncology products across Central and Eastern Europe (CEE) and Turkey.
Global Pharma | 26/08/2025 | By Dineshwori | 341
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy